Results 1 to 10 of about 50,237 (216)

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy

Frontiers in Oncology, 2021
The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as cetuximab, poses a challenging problem.
Hannah Zaryouh, Ines De Pauw, Hasan Baysal, Patrick Pauwels, Patrick Pauwels, Marc Peeters, Marc Peeters, Jan Baptist Vermorken, Jan Baptist Vermorken, Filip Lardon, An Wouters   +10 more
doaj   +1 more source

Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT

Cancer Reports, 2022
Background Cetuximab plus platinum‐based therapy (PBT) followed by cetuximab maintenance until progression (EXTREME) is a guideline‐recommended first‐line treatment option in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN ...
Joël Guigay, Emmanuel Chamorey, Gautier Lefebvre, Maciej Rotarski, Jean‐Philippe Wagner, Emmanuel Blot, Marc Alfonsi, Audrey Seronde, Jeltje Schulten, Frédéric Peyrade, Christophe Le Tourneau   +10 more
doaj   +1 more source

Production and evaluation of cellular effects of 153Sm-DOTA-cetuximab and 177Lu-DOTA-cetuximab radioconjugates [PDF]

مجله علوم و فنون هسته‌ای, 2023
Antibody-based radiopharmaceuticals are of increasing interest today in cancer imaging and radiotherapy. The cetuximab monoclonal antibody binds to the epidermal growth factor receptor (EGFR) and thus provides therapeutic and diagnostic protocols against
K. Yavari, M. Ghanadi Maragheh
doaj   +1 more source

Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells. [PDF]

PLoS ONE, 2013
Cetuximab is a chimeric mouse-human monoclonal antibody that targets the human epidermal growth factor receptor (EGFR). However, EGFR expression determined by immunohistochemistry does not predict clinical outcomes of colorectal cancer (CRC) patients ...
Kohei Shigeta, Tetsu Hayashida, Yoshinori Hoshino, Koji Okabayashi, Takashi Endo, Yoshiyuki Ishii, Hirotoshi Hasegawa, Yuko Kitagawa   +7 more
doaj   +1 more source

AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

BMC Cancer, 2022
Background The receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) is overexpressed and an important therapeutic target in Head and Neck cancer (HNC).
Mari Iida, Nellie K. McDaniel, Kourtney L. Kostecki, Noah B. Welke, Carlene A. Kranjac, Peng Liu, Colin Longhurst, Justine Y. Bruce, Seungpyo Hong, Ravi Salgia, Deric L. Wheeler   +10 more
doaj   +1 more source

RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab

BMC Cancer, 2023
Background Radioimmunotherapy with cetuximab and conjugates with various radioisotopes is a feasible treatment option for different tumor models. Scandium-47 (47Sc), one of several β−-particle-emitting radioisotopes, displays favorable physical and ...
Da-Mi Kim, So-Young Lee, Jae-Cheong Lim, Eun-Ha Cho, Ul-Jae Park   +4 more
doaj   +1 more source

Exploring the Application of Bifunctional Metal Chelators in Treating Triple-Negative Breast Cancer

Frontiers in Bioengineering and Biotechnology, 2021
Purpose: In this study, we independently synthesised and labelled a novel bidentate bifunctional chelating agent, 177Lu-3,4-HOPO-Cetuximab, that achieved tight binding between targeting and radioactivity, and evaluated its targeted killing ability of ...
Kuo Li, Kuo Li, Youjiu Zhang, Xiaomei Wang, Ran Zhu, Changsheng Ma, Rui Hu   +6 more
doaj   +1 more source

Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection

World Allergy Organization Journal, 2021
Background: Cetuximab (chimeric monoclonal antibody to human epidermal growth factor receptor) is used to treat colorectal and head and neck cancers. Due to cross-reactivity with galactose-α-1,3-galactose (alpha-gal), it can induce hypersensitivity even ...
Kyung Hee Park, Jongsun Lee, Seung Hoon Beom, Sang Joon Shin, Joong Bae Ahn, Sung-Ryeol Kim, Jae-Hyun Lee, Jung-Won Park   +7 more
doaj   +1 more source

Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.

PLoS ONE, 2020
The epidermal growth factor receptor inhibitor cetuximab is the only oncogene-targeted agent that has been FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC).
Rachel A O'Keefe, Neil E Bhola, David S Lee, Daniel E Johnson, Jennifer R Grandis   +4 more
doaj   +1 more source

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer

Cellular Physiology and Biochemistry, 2017
Background/Aims: Cetuximab is a chimeric IgG1 monoclonal antibody which targets the extracellular domain of epidermal growth factor receptor. This antibody is widely used for colorectal cancer (CRC) treatment but its influence on the immune system is ...
Lin Wang, Yingfeng Wei, Weijia Fang, Chong Lu, Jianing Chen, Guangying Cui, Hongyan Diao   +6 more
doaj   +1 more source